Breaking News, Collaborations & Alliances

CureVac, MD Anderson Enter Strategic Cancer Vax Pact

Aims to develop differentiated cancer vaccine candidates in selected hematological and solid tumor indications.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac N.V., a global biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), and The University of Texas MD Anderson Cancer Center entered a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.   The collaboration leverages CureVac’s capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters